Platforms
STAR-T Platform
STAR utilizes a dual-chain antibody-TCR chimera that fully mimick the native TCR-CD3 signaling pathway, MHC-independent.
-
-
STAR-T Platform: Native TCR Signaling, Superior to CAR-T
See details about STAR-TSTAR-T platformSTAR-T platform
1. Ultra-high sensitivity: 10–100× higher antigen sensitivity than conventional CAR-T (Sci Transl Med 2021; Cell Rep 2024)
2. Superior tissue infiltration: Deep penetration into tissues, effective for severe autoimmune diseases and solid tumors (Sci Transl Med 2021)
3. Excellent safety: Mild adverse events (ASH 2020; Am J Hematol 2022)
Off-the-shelf STAR-T Platform
One-step TRAC editing achieves TCR knockout and STAR site-specific insertion for universal off-the-shelf T-cell therapy.
-
-
Off-the-shelf STAR-T Platform: One-Step Integration, Universal Cell Therapy
See details about Off-the-shelf STAR-TSTAR-T platformOff-the-shelf STAR-T Platform
1. Precise integration: No random insertion risk; STAR replaces endogenous TCR with no severe GVHD (Nat Med 2025)
2. Low cost: 1/20 the cost of autologous CAR-T, scalable industrial production
3. Full function compensation: Restores TCR signaling, sustains T-cell activity (Sci Transl Med 2021)
In vivo STAR-T Platform
In vivo STAR-T generates therapeutic T cells in situ via non-invasive delivery, bypassing ex vivo manufacturing limits.
-
-
In vivo STAR-T Platform: In Situ T-Cell Generation, Safer In Vivo Therapy
See details about In vivo STAR-TSTAR-T platformIn vivo STAR-T Platform
1. Precise T-cell targeting: Specific activation in T cells, exceptional safety
2. Efficient transduction: Potently targets quiescent T cells with validated preclinical data
3. Clinical pipeline: First-in-human data expected Q4 2026